By combining MSI and BRAF mutational status, Seppälä et al. have demonstrated that BRAF-mutated MSI tumors were associated with a better prognosis than BRAF-mutated MSS CRC tumors [42]. The gene discussed is BRAF; the disease is colorectal carcinoma.